Enhanced anti-tumor efficacy and safety profile of tumor microenvironment-responsive oncolytic adenovirus nanocomplex

Joung-Woo Choi1, Kasala Dayananda1, Soo-Jung Jung1

  • 1Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 133-791, Republic of Korea.

Acta Biomaterialia
|September 15, 2015
PubMed

Insights

Coating oncolytic adenoviruses (Ad) with a pH-sensitive polymer, mPEG-b-pHis, enhances cancer gene therapy. This hybrid vector targets tumors, improves transduction, and reduces immune response for better therapeutic efficacy.

Area of Science:

  • Oncolytic virotherapy
  • Polymer-drug conjugates
  • Cancer gene therapy

Background:

  • Oncolytic adenoviruses (Ad) show promise for cancer gene therapy but face challenges like immune responses and non-specific targeting.
  • Systemic administration of Ad is hindered by host immune reactions and tumor heterogeneity.

Purpose of the Study:

  • To develop a hybrid vector system combining oncolytic Ad with a pH-sensitive polymer, methoxy poly(ethylene glycol)-b-poly(l-histidine) (mPEG-b-pHis), to improve cancer targeting and therapeutic efficacy.
  • To evaluate the in vitro and in vivo performance of Ad complexed with mPEG-b-pHis for enhanced tumor targeting and reduced immune response.

Main Methods:

  • Adenovirus (Ad) was complexed with the pH-sensitive block copolymer mPEG-b-pHis to create a hybrid vector.
  • In vitro studies assessed transduction efficiency at acidic vs. neutral pH and cellular uptake rates using GFP-expressing Ad.
  • In vivo studies evaluated therapeutic efficacy, tumor-specific viral replication, immune response, and biodistribution using luciferase-expressing oncolytic Ad in tumor models.

Main Results:

  • The mPEG-b-pHis-coated Ad (c-dE1/GFP) demonstrated significantly enhanced in vitro transduction efficiency in cancer cells at acidic pH compared to naked Ad.
  • Time-lapse imaging showed increased cellular uptake of c-dE1/GFP at acidic tumor pH.
  • Systemic administration of the mPEG-b-pHis-coated oncolytic Ad (c-H5mT/Luc) resulted in enhanced therapeutic efficacy, tumor growth suppression, and reduced liver accumulation compared to naked Ad.
  • The hybrid vector significantly reduced innate and adaptive immune responses against the Ad.

Conclusions:

  • The Ad/mPEG-b-pHis hybrid vector system exhibits pH-dependent targeting and enhanced cancer cell-killing effects.
  • Systemic administration of oncolytic Ad/mPEG-b-pHis leads to marked tumor growth suppression and tumor-specific viral replication.
  • The mPEG-b-pHis coating effectively shields Ad from immune responses and reduces liver accumulation, improving its potential for cancer gene therapy.

Related Concept Videos